FBLG

FibroBiologics Inc

Apr 02 • 04:00PM ET

1.38

+0.05 3.76 %

Healthcare • Biotechnology • USA • NASD

Apr 02, 4:05 PMFibroBiologics closes best-efforts public offering raising approximately $3 million in gross proceeds

Peers: JNJ MRK PFE GILD LLY BMY AMGN REGN VRTX BIIB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.78	Insider Own	18.26%	Shs Outstand	3.33M	Perf Week	-68.64%
Market Cap	4.85M	Forward P/E	-	EPS next Y	-4.32	Insider Trans	106.85%	Shs Float	2.87M	Perf Month	-81.63%
Enterprise Value	2.37M	PEG	-	EPS next Q	-1.36	Inst Own	6.69%	Short Float	1.52%	Perf Quarter	-69.32%
Income	-18.65M	P/S	-	EPS this Y	49.88%	Inst Trans	-3.13%	Short Ratio	0.15	Perf Half Y	-86.81%
Sales	0.00M	P/B	0.75	EPS next Y	-2.61%	ROA	-89.89%	Short Interest	0.04M	Perf YTD	-69.32%
Book/sh	1.85	P/C	0.99	EPS next 5Y	14.83%	ROE	-419.44%	52W High	30.60 -95.49%	Perf Year	-92.63%
Cash/sh	1.39	P/FCF	-	EPS past 3/5Y	-38.37% -71.12%	ROIC	-237.23%	52W Low	1.03 33.98%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	47.59% 22.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-30.18%	Oper. Margin	-	ATR (14)	0.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	20.90	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	3.61	EPS Q/Q	46.47%	SMA20	-72.70%	Beta	1.08	Target Price	95.00
Payout	-	Debt/Eq	0.39	Sales Q/Q	-	SMA50	-75.59%	Rel Volume	2.76	Prev Close	1.33
Employees	15	LT Debt/Eq	0.28	Earnings	Feb 24 AMC	SMA200	-83.85%	Avg Volume	288.63K	Price	1.38
IPO	Jan 31, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	35.42% -	Trades		Volume	797,417	Change	3.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Initiated	Rodman & Renshaw	Buy	$12
Oct-30-24	Initiated	H.C. Wainwright	Buy	$12
Sep-24-24	Initiated	Maxim Group	Buy	$12

Apr-02-26 04:01PM	FibroBiologics Announces Closing of $3 Million Public Offering (GlobeNewswire)
Mar-31-26 08:00PM	FibroBiologics Announces Pricing of $3 Million Public Offering (GlobeNewswire) -42.11%
04:15PM	FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial (GlobeNewswire)
Mar-25-26 04:30PM	FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement (GlobeNewswire) -16.51%
Mar-12-26 08:30AM	FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology (GlobeNewswire)
08:30AM	Loading…
Mar-05-26 08:30AM	FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (GlobeNewswire) +11.58%
Mar-03-26 10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire) -7.22%
Mar-02-26 08:30AM	FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis (GlobeNewswire) +27.66%
Feb-26-26 08:30AM	FibroBiologics to Present at the BIO Investment & Growth Summit (GlobeNewswire) +7.44%
Feb-24-26 04:30PM	FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.73%
Feb-23-26 08:30AM	FibroBiologics Granted Extension by Nasdaq to Regain Compliance (GlobeNewswire)
Feb-10-26 08:30AM	FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University (GlobeNewswire) +6.24%
Feb-05-26 08:30AM	FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia (GlobeNewswire) -9.20%
Jan-20-26 08:30AM	FibroBiologics to Present at the DealFlow Discovery Conference (GlobeNewswire)
Jan-07-26 08:30AM	FibroBiologics CEO Issues Letter to Shareholders (GlobeNewswire) +32.27%
08:30AM	Loading…
Jan-06-26 08:30AM	FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference (GlobeNewswire) +6.78%
Jan-05-26 08:30AM	FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease (GlobeNewswire)
Dec-31-25 08:30AM	FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis (GlobeNewswire) -7.03%
Dec-16-25 04:05PM	FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -8.44% +14.53%
Dec-15-25 08:00AM	FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -33.06%
Dec-10-25 08:30AM	FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions (GlobeNewswire) +12.82%
Nov-26-25 08:30AM	FibroBiologics Announces Payoff of Outstanding Debt (GlobeNewswire)
Nov-25-25 04:05PM	FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Nov-24-25 09:00AM	FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.53%
Nov-20-25 08:00AM	FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers (GlobeNewswire) -5.78%
Nov-19-25 07:03PM	FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:36AM	FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-31-25 04:30PM	FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-25 08:30AM	FibroBiologics to Present at Bio-Europe 2025 (GlobeNewswire) +6.28%
Oct-14-25 08:30AM	FibroBiologics to Present at the 2025 ThinkEquity Conference (GlobeNewswire)
08:30AM	Loading…
Sep-23-25 08:30AM	FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-12-25 08:30AM	FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies (GlobeNewswire)
Sep-11-25 08:30AM	FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment (GlobeNewswire)
Sep-10-25 08:30AM	FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies (GlobeNewswire)
Aug-27-25 08:30AM	FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Jul-31-25 04:30PM	FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-25 08:30AM	FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications (GlobeNewswire)
Jul-11-25 08:30AM	FibroBiologics to Present at the Advanced Wound Care Summit USA (GlobeNewswire)
Jul-09-25 08:30AM	FibroBiologics Confirms Ability to Manufacture CybroCell for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank (GlobeNewswire) +9.04%
Jul-07-25 04:35PM	FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 (GlobeNewswire)
Jun-16-25 04:35PM	FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.48%
09:50AM	FibroBiologics to Present at the BIO International Convention 2025 (GlobeNewswire)
Jun-09-25 08:30AM	FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer (GlobeNewswire)
May-16-25 08:30AM	FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -8.42%
May-14-25 04:30PM	FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +22.67%
Apr-29-25 09:15AM	FibroBiologics Presents at the ThymUS 2025 Meeting (GlobeNewswire) -8.37%
09:15AM	FibroBiologics Presenting at the ThymUS 2025 Meeting (GlobeNewswire)
Apr-11-25 08:30AM	FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean (GlobeNewswire) +9.50%
Apr-08-25 08:30AM	FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics (GlobeNewswire) -6.31%
Apr-02-25 08:30AM	FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair (GlobeNewswire) +8.88%
Mar-31-25 04:25PM	FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.26%
Mar-27-25 08:30AM	FibroBiologics Announces 2025 Annual Meeting of Stockholders (GlobeNewswire)
Mar-21-25 08:30AM	FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting (GlobeNewswire) +7.77%
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-04-25 08:30AM	FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics (GlobeNewswire) +6.99%
Feb-27-25 08:30AM	FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic (GlobeNewswire)
Feb-05-25 09:15AM	FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates (GlobeNewswire) +6.45%
Dec-30-24 04:30PM	FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.08% -10.71%
02:12PM	D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing (GlobeNewswire)
Dec-23-24 07:55AM	FibroBiologics Announces $25 Million Financing (GlobeNewswire) -6.67%
Nov-19-24 09:15AM	FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly (GlobeNewswire)
Nov-14-24 09:15AM	FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics (GlobeNewswire) -8.77%
Nov-12-24 04:20PM	FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.12%
Oct-29-24 09:15AM	FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology (GlobeNewswire)
Oct-28-24 09:31AM	FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 (GlobeNewswire)
Oct-21-24 07:45AM	FibroBiologics and Charles River link for chronic disease therapies manufacture (Pharmaceutical Technology) -9.88%
Oct-18-24 08:30AM	FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases (GlobeNewswire)
Oct-16-24 09:15AM	FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office (GlobeNewswire) +17.82%
Oct-11-24 09:31AM	FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +12.07%
Sep-30-24 09:31AM	FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-19-24 09:31AM	FibroBiologics Engages Southern Star Research as CRO in Australia (GlobeNewswire)
Sep-12-24 09:31AM	FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology (GlobeNewswire) -7.60%
Sep-06-24 09:31AM	FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +12.37%
Aug-20-24 09:31AM	FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology (GlobeNewswire)
Aug-07-24 06:52PM	FibroBiologics Files 2024 Second Quarter Report (GlobeNewswire) -39.41%
Jul-15-24 09:31AM	FibroBiologics to Present at JonesTrading Healthcare Summit 2024 (GlobeNewswire) +5.49%
Jun-25-24 09:31AM	FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology (GlobeNewswire)
Jun-13-24 09:31AM	FibroBiologics Set to Join Russell 2000 Index (GlobeNewswire) -6.14%
Jun-06-24 09:31AM	FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024 (GlobeNewswire) +53.88%
May-15-24 04:30PM	FibroBiologics Announces 2024 Annual Meeting of Stockholders (GlobeNewswire)
09:54AM	FBLG Stock Earnings: FibroBiologics, Inc. - Common Stock Reported Results for Q1 2024 (InvestorPlace)
May-14-24 05:24PM	FibroBiologics Files 2024 First Quarter Report (GlobeNewswire) +10.35%
May-07-24 09:31AM	FibroBiologics to Present at the BIO International Convention 2024 (GlobeNewswire) +5.49%
Apr-25-24 08:00AM	FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids (GlobeNewswire)
Apr-11-24 09:31AM	FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office (GlobeNewswire)
Apr-04-24 09:31AM	FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA (GlobeNewswire)
Mar-28-24 09:31AM	FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus (GlobeNewswire) -8.00%
Mar-19-24 09:31AM	FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment (PR Newswire) +21.36%
Mar-13-24 09:31AM	FibroBiologics to Present at Advanced Wound Care Summit USA (PR Newswire) -5.83%
Mar-06-24 09:31AM	FibroBiologics Appoints Ruben A. Garcia as General Counsel (PR Newswire)
Feb-29-24 05:44PM	FibroBiologics Files 2023 Form 10-K Annual Report (PR Newswire)
Feb-20-24 09:31AM	FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum (PR Newswire) -8.52%
Feb-13-24 09:31AM	FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases (PR Newswire) +88.38%
Feb-08-24 09:31AM	FibroBiologics Announces Three United States Patents for Fibroblast Technology (PR Newswire) -9.91%
Feb-06-24 09:31AM	FibroBiologics Announces Three Japanese Patents on Fibroblast Technology (PR Newswire) -28.26%
Jan-31-24 10:00AM	FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG (PR Newswire)

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khoja Hamid	Chief Scientific Officer	Mar 04 '26	Buy	0.38	30,000	11,400	61,250	Mar 05 08:00 AM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 03 '26	Buy	0.41	18,200	7,373	5,942,275	Mar 04 05:50 PM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 02 '26	Buy	0.35	17,428	6,152	5,924,075	Mar 04 05:50 PM
O'HEERON PETE	CHIEF EXECUTIVE OFFICER	Mar 04 '26	Buy	0.38	15,872	6,006	5,958,147	Mar 04 05:50 PM
Davis Jason	Chief Financial Officer	Mar 02 '26	Buy	0.41	70,000	28,973	70,000	Mar 03 08:00 AM
GARCIA RUBEN A	General Counsel	Feb 27 '26	Buy	0.33	40,000	13,056	180,000	Mar 02 09:15 AM
GARCIA RUBEN A	General Counsel	Dec 11 '25	Buy	0.34	140,000	47,600	140,000	Dec 12 07:16 AM
Khoja Hamid	Chief Scientific Officer	May 27 '25	Buy	0.84	20,000	16,800	31,250	May 27 05:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBLG

FibroBiologics Inc

Upgrade your Finviz experience